AbbVie focuses on key therapeutic areas including immunology, neuroscience and oncology, with products and services in its Allergan Aesthetics portfolio. The company has strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). In January 2026, AbbVie struck a deal with the Trump administration to invest $100 billion in its US operations over the next 10 years and lower Medicaid prices, with the administration exempting AbbVie from tariffs and future pricing mandates.
Cyborg Score Rationale
The company's shares are up 29% in 2025 and it has robust underlying operations, a strong outlook through the next decade, and offers an exceptional dividend program. However, 2024 results showed net income falling 15% while operating expenses and EBIT declined 23%, reflecting profitability challenges despite stable revenues.
Top Insights
Management expects another year of robust growth in 2026, with momentum combined with investments in innovation positioning AbbVie for long-term success.
Growth drivers include schizophrenia treatment Vraylar and migraine medicine Qulipta, though the U.S. government has targeted Vraylar for drug price negotiations with negotiated prices taking effect in 2027.
The company maintains a consistent dividend payment track record with annual yield around 3.5%, and dividends are well covered by free cash flow.
AbbVie expects no loss of patent exclusivity for a major growth driver through the end of the decade.
Named Competitors
Keytruda — Oncology/immunotherapy
Opdivo — Oncology/immunotherapy
Dupixent — Immunology/dermatology
Cosentyx — Immunology
Recent Developments
(February 2026) Full-year 2025 earnings exceed expectations with record net sales; 2026 adjusted diluted EPS guidance of $14.37-$14.57
(January 2026) $100 billion U.S. investment commitment and agreement with Trump administration on drug pricing
(December 2025) 2025 revenue increased 8% YoY to $44.5B through nine months with strong performance from Skyrizi and Rinvoq
Open the full interactive AbbVie Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.